Evaluating the Efficacy of a Text Messaging-based Shisha Smoking Cessation Intervention
Launched by THE UNIVERSITY OF HONG KONG · Jul 14, 2025
Trial Information
Current as of July 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to help young adults in Hong Kong quit smoking shisha (also known as hookah or waterpipe). The study will compare two groups: one group will receive helpful and personalized text messages on their smartphones for six weeks, designed to encourage quitting and provide support, while the other group will get a simple leaflet with information about the health risks of shisha smoking. The researchers want to see if the text messaging program works better than just giving out information in helping people stop smoking shisha.
To take part, you need to be between 18 and 35 years old, have smoked shisha at least once in the past month, and have smoked regularly over the past year. You also need to be able to read and understand Chinese or English and be willing to use your own phone to send and receive messages. During the study, participants will fill out short questionnaires three times: before starting, at 6 weeks, and at 12 weeks. These will ask about how much they have smoked, what they know about the risks, and how ready they feel to quit. This study is not yet recruiting participants, but if you are interested and meet the criteria, it could be a helpful way to get support to stop smoking shisha.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • young adults aged 18 to 35 years who are interested in quitting shisha
- • smoked shisha within the 30 days at the time of enrolment (current smoker)
- • smoked for more than twelve times in 12 months (i.e., on a monthly basis)22
- • able to read and communicate in Chinese or English
- • agree to utilise his/her own personal mobile or smartphone to send and receive messages
- Exclusion Criteria:
- • scored 10 (''have already quitted'') on Contemplation Ladder assessment at baseline
- • unable to provide consent
- • unable to read and communicate in Chinese or English
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Johnson Kai Chun Law, MSc
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported